Wells Fargo & Company Cuts Amicus Therapeutics (NASDAQ:FOLD) Price Target to $17.00

Amicus Therapeutics (NASDAQ:FOLD) had its price objective trimmed by Wells Fargo & Company from $18.00 to $17.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently commented on FOLD. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Morgan Stanley restated an “equal weight” rating and set a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. JPMorgan Chase & Co. boosted their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.75.

Amicus Therapeutics Stock Up 1.3 %

FOLD opened at $9.19 on Thursday. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The company has a market cap of $2.82 billion, a PE ratio of -51.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.61. The firm has a 50 day moving average price of $9.56 and a 200 day moving average price of $10.41. Amicus Therapeutics has a 1 year low of $8.78 and a 1 year high of $14.02.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total transaction of $75,150.00. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at $8,884,273.08. The trade was a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 2.20% of the company’s stock.

Institutional Trading of Amicus Therapeutics

Institutional investors have recently made changes to their positions in the business. Summit Investment Advisors Inc. lifted its stake in Amicus Therapeutics by 4.4% during the fourth quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 1,280 shares during the period. Hazlett Burt & Watson Inc. raised its holdings in shares of Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,569 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Amicus Therapeutics by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 1,884 shares in the last quarter. Xponance Inc. lifted its position in shares of Amicus Therapeutics by 11.9% during the 4th quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 2,249 shares during the period. Finally, Covestor Ltd boosted its stake in Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 2,312 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.